Literature DB >> 11496344

Proliferative and apoptotic differences between alveolar rhabdomyosarcoma subtypes: a comparative study of tumors containing PAX3-FKHR or PAX7-FKHR gene fusions.

M H Collins1, H Zhao, R B Womer, F G Barr.   

Abstract

BACKGROUND: Most alveolar rhabdomyosarcomas (ARMS) have chromosome translocations and resultant gene fusion products. The more common translocation fuses the PAX3 and FKHR genes; patients who have PAX3-FKHR-positive ARMS have reduced event-free survival compared to patients with ARMS containing the less common translocation that fuses the PAX7 and FKHR genes. PROCEDURE: We examined histology, immunohistochemical markers of differentiation, and cell cycle characteristics of a panel of ARMS containing either PAX3-FKHR or PAX7-FKHR transcript to determine if these features differ between the ARMS subsets.
RESULTS: Cell cycle parameters varied significantly: the number of nuclei that stained with either an immunohistochemical marker of proliferation (MIB1), or a TUNEL-based assay for apoptosis was significantly greater in tumors that expressed PAX3-FKHR compared to tumors that expressed PAX7-FKHR transcript.
CONCLUSIONS: We conclude that compared to PAX7-FKHR-containing tumors, ARMS that contain PAX3-FKHR transcript have (1) increased cell proliferation, consistent with greater loss of cell cycle regulation, and (2) apoptosis that is increased but insufficient to prevent tumor formation. More marked cell cycle dysregulation may contribute to poorer prognosis for patients with ARMS that have PAX3-FKHR fusion. Med Pediatr Oncol 2001;37:83-89. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11496344     DOI: 10.1002/mpo.1174

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  21 in total

1.  Macrophage migration inhibitory factor is secreted by rhabdomyosarcoma cells, modulates tumor metastasis by binding to CXCR4 and CXCR7 receptors and inhibits recruitment of cancer-associated fibroblasts.

Authors:  Maciej Tarnowski; Katarzyna Grymula; Rui Liu; Joanna Tarnowska; Justyna Drukala; Janina Ratajczak; Robert A Mitchell; Mariusz Z Ratajczak; Magda Kucia
Journal:  Mol Cancer Res       Date:  2010-09-22       Impact factor: 5.852

Review 2.  Role of genetic and molecular profiling in sarcomas.

Authors:  Scott M Norberg; Sujana Movva
Journal:  Curr Treat Options Oncol       Date:  2015-05

3.  Thrombin regulates the metastatic potential of human rhabdomyosarcoma cells: distinct role of PAR1 and PAR3 signaling.

Authors:  Marcin Wysoczynski; Rui Liu; Magda Kucia; Justyna Drukala; Mariusz Z Ratajczak
Journal:  Mol Cancer Res       Date:  2010-05-04       Impact factor: 5.852

Review 4.  Risk assignment in pediatric soft-tissue sarcomas: an evolving molecular classification.

Authors:  Stephen J Qualman; Raffaella A Morotti
Journal:  Curr Oncol Rep       Date:  2002-03       Impact factor: 5.075

5.  Pax3-FKHR knock-in mice show developmental aberrations but do not develop tumors.

Authors:  Irina Lagutina; Simon J Conway; Jack Sublett; Gerard C Grosveld
Journal:  Mol Cell Biol       Date:  2002-10       Impact factor: 4.272

Review 6.  PAX3-FOXO1 fusion gene in rhabdomyosarcoma.

Authors:  Corinne M Linardic
Journal:  Cancer Lett       Date:  2008-05-23       Impact factor: 8.679

7.  Bioactive lipids S1P and C1P are prometastatic factors in human rhabdomyosarcoma, and their tissue levels increase in response to radio/chemotherapy.

Authors:  Gabriela Schneider; Ewa Bryndza; Ahmed Abdel-Latif; Janina Ratajczak; Magdalena Maj; Maciej Tarnowski; Yuri M Klyachkin; Peter Houghton; Andrew J Morris; Axel Vater; Sven Klussmann; Magdalena Kucia; Mariusz Z Ratajczak
Journal:  Mol Cancer Res       Date:  2013-04-24       Impact factor: 5.852

Review 8.  Myogenin and MyoD1 expression in paediatric rhabdomyosarcomas.

Authors:  N J Sebire; M Malone
Journal:  J Clin Pathol       Date:  2003-06       Impact factor: 3.411

9.  Bioactive lipids, LPC and LPA, are novel prometastatic factors and their tissue levels increase in response to radio/chemotherapy.

Authors:  Gabriela Schneider; Zachariah Payne Sellers; Ahmed Abdel-Latif; Andrew J Morris; Mariusz Z Ratajczak
Journal:  Mol Cancer Res       Date:  2014-07-17       Impact factor: 5.852

10.  Regulation of expression of stromal-derived factor-1 receptors: CXCR4 and CXCR7 in human rhabdomyosarcomas.

Authors:  Maciej Tarnowski; Katarzyna Grymula; Ryan Reca; Kacper Jankowski; Radoslaw Maksym; Joanna Tarnowska; Grzegorz Przybylski; Frederic G Barr; Magdalena Kucia; Mariusz Z Ratajczak
Journal:  Mol Cancer Res       Date:  2010-01-12       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.